mRNA-LNP Programming of CAR Macrophages for Peritoneal Cancer Immunotherapy

Study Background and Research Question

Peritoneal metastasis remains a major clinical challenge in the management of advanced solid tumors. Conventional therapies, such as cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC), are only suitable for a subset of patients with minimal tumor burden, leaving most cases without effective treatment options. Immunotherapy has shown promise in overcoming tumor immune evasion, but the immunosuppressive microenvironment of peritoneal tumors often limits therapeutic efficacy. Given that macrophages are abundant within peritoneal ascites and play dynamic roles in immune modulation, there is strong interest in leveraging these cells for therapeutic benefit. The core research question addressed by Gu et al. is whether intraperitoneal, in situ programming of macrophages with tailored chimeric antigen receptors (CARs) via mRNA lipid nanoparticles could offer a broadly applicable and effective immunotherapy for peritoneal metastases (Gu et al., 2025).

Key Innovation from the Reference Study

The primary innovation of this study is the development of a macrophage-targeted mRNA-LNP delivery system capable of programming resident peritoneal macrophages in vivo to express a wide range of CAR constructs. Unlike traditional ex vivo cell engineering, this approach enables direct and flexible modulation of immune effector functions within the tumor microenvironment. The researchers systematically evaluated 36 CAR intracellular domain (ICD) configurations, ultimately identifying a CD3ζ-TLR4 ICD combination that imparted robust adaptive immune activation and synergized with PD-1/L1 immune checkpoint blockade.

Methods and Experimental Design Insights

The study employed a comprehensive experimental framework to design, deliver, and evaluate CAR-Ms:

• Construction of a panel of 36 CARs with diverse ICDs, optimizing for signaling potency and macrophage compatibility.
• Formulation of mRNA-LNPs engineered for preferential uptake by macrophages in the peritoneal cavity, enabling in situ transfection without ex vivo manipulation.
• Single-cell RNA sequencing (scRNA-seq) to characterize transcriptional changes in both CAR-Ms and the broader tumor microenvironment following treatment.
• Functional assays to assess antitumor activity, immune cell recruitment, and synergy with checkpoint blockade therapy.
• Use of ATP-dependent bioluminescence assays, which in similar workflows often employ D-Luciferin sodium salt as a firefly luciferase substrate for quantitative assessment of cell viability and metabolic activity (see also related internal discussion).

Protocol Parameters

• CAR mRNA-LNP dosing: Intraperitoneal administration; dosing schedule tailored to tumor model and immune readouts.
• CAR construct screening: Systematic comparison of 36 ICDs; CD3ζ-TLR4 identified as optimal for immune activation.
• scRNA-seq timepoints: Tumor and immune cell profiling performed post-CAR-M programming and after combination therapy.
• Checkpoint blockade synergy: Combination with PD-1/L1 inhibitors evaluated for additive/synergistic effects.
• Bioluminescence imaging: Standard luciferase-based assays for in vivo and ex vivo cell tracking, using D-Luciferin as the substrate for ATP-dependent signal generation.

Core Findings and Why They Matter

The in situ programming of peritoneal macrophages with mRNA-LNPs encoding tailored CARs led to several notable outcomes:

• Robust adaptive immune activation: CAR-Ms with CD3ζ-TLR4 ICDs induced strong proinflammatory phenotypes and enhanced antigen presentation, promoting adaptive T cell responses.
• Synergy with immune checkpoint blockade: The combination of CAR-Ms and PD-1/L1 inhibitors significantly amplified antitumor effects, as measured by tumor regression and increased infiltration of effector immune cells.
• Remodeling of the tumor microenvironment: scRNA-seq revealed an increase in progenitor-exhausted TCF1+PD-1+ CD8+ T cells (Tpex), a population associated with durable responses to immunotherapy, and upregulation of MHC-I and PDL1 expression in CAR-Ms via NF-κB pathway modulation.
• Feasibility of intraperitoneal delivery: Direct programming of endogenous macrophages bypasses the need for complex cell manufacturing, potentially streamlining clinical translation.

These findings offer new avenues for targeting immunologically "cold" tumor sites and highlight the versatility of mRNA-LNP technologies in cellular therapy engineering.

Comparison with Existing Internal Articles

Several recent reviews and technical articles have discussed the role of D-Luciferin sodium salt in supporting ATP-dependent bioluminescence assays across immunotherapy workflows. For example, one mechanistic review contextualizes the use of D-Luciferin-based bioluminescence imaging for tracking CAR-modified immune cells and quantifying metabolic activity in translational oncology models. Similarly, an optimization article details practical enhancements to firefly luciferase assay workflows using high-purity substrates, noting the importance of reagent quality for reproducibility and sensitivity. These internal resources complement the reference study by highlighting best practices for using bioluminescent imaging to monitor cell viability, metabolic state, and therapeutic efficacy—methodologies that underpin the experimental rigor in Gu et al.'s mRNA-LNP CAR-M workflow.

Limitations and Transferability

Despite its promise, the study by Gu et al. faces several limitations. The in vivo models employed may not fully capture the complexity of human peritoneal metastases, and the safety profile of repeated intraperitoneal mRNA-LNP administration requires further clarification. The durability of CAR expression and the long-term fate of programmed macrophages also remain to be determined. While the platform demonstrates strong potential in peritoneal settings, its applicability to other metastatic or immune-privileged sites will require additional investigation. Nonetheless, the modular nature of mRNA-LNP delivery offers a flexible template for rapid adaptation to diverse clinical scenarios.

Research Support Resources

For researchers aiming to implement similar ATP-dependent bioluminescence assays or track CAR-modified immune cell dynamics, D-Luciferin sodium salt (SKU B8311) from APExBIO provides a high-purity, well-characterized firefly luciferase substrate suitable for sensitive cell viability and metabolism monitoring. Its robust solubility profile and compatibility with standard luciferase workflows make it a practical choice for experiments requiring quantitative bioluminescence imaging in oncology and immunotherapy research. For further workflow guidance and troubleshooting, consult these internal resources for in-depth assay strategies.